These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 35147675)

  • 1. Cost-effectiveness analysis of alternative anticoagulation in suspected heparin-induced thrombocytopenia.
    Tuleja A; Salvador D; Muka T; Bernhard S; Lenz A; Baumgartner I; Schindewolf M
    Blood Adv; 2022 May; 6(10):3114-3125. PubMed ID: 35147675
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of anticoagulants for suspected heparin-induced thrombocytopenia in the United States.
    Aljabri A; Huckleberry Y; Karnes JH; Gharaibeh M; Kutbi HI; Raz Y; Yun S; Abraham I; Erstad B
    Blood; 2016 Dec; 128(26):3043-3051. PubMed ID: 27793877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of Fondaparinux Off-Label or Approved Anticoagulants for Management of Heparin-Induced Thrombocytopenia.
    Schindewolf M; Steindl J; Beyer-Westendorf J; Schellong S; Dohmen PM; Brachmann J; Madlener K; Pötzsch B; Klamroth R; Hankowitz J; Banik N; Eberle S; Müller MM; Kropff S; Lindhoff-Last E
    J Am Coll Cardiol; 2017 Nov; 70(21):2636-2648. PubMed ID: 29169470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel fondaparinux protocol for anticoagulation therapy in adults with renal failure and suspected heparin-induced thrombocytopenia: a retrospective review of institutional protocol.
    Ghaziri D; Dehaini H; Msheik M; Bahmad M; Zorkot M; Saad GA
    BMC Pharmacol Toxicol; 2023 Jan; 24(1):2. PubMed ID: 36639796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heparin-induced thrombocytopenia: pathophysiology, diagnosis and treatment.
    Hvas AM; Favaloro EJ; Hellfritzsch M
    Expert Rev Hematol; 2021 Apr; 14(4):335-346. PubMed ID: 33736552
    [No Abstract]   [Full Text] [Related]  

  • 6. Bleeding and Thrombotic Adverse Events in Hospitalized Patients Under Empiric Treatment for Suspected Heparin-Induced Thrombocytopenia While Awaiting Confirmatory Testing.
    Dykes KC; Johnson CA; Gong JZ; McKenzie SE; Husseinzadeh HD
    Clin Appl Thromb Hemost; 2021; 27():1076029621996473. PubMed ID: 33848189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of argatroban and fondaparinux for the management of patients with isolated heparin-induced thrombocytopenia.
    Al-Eidan FAS; Alrawkan S; Alshammary H; Crowther MA
    Ann Hematol; 2018 Nov; 97(11):2055-2059. PubMed ID: 30003318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Fondaparinux in Patients With Suspected Heparin-Induced Thrombocytopenia.
    Snodgrass MN; Shields J; Rai H
    Clin Appl Thromb Hemost; 2016 Nov; 22(8):712-717. PubMed ID: 27179015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rivaroxaban as an Alternative Agent for Heparin-Induced Thrombocytopenia.
    Farasatinasab M; Zarei B; Moghtadaei M; Nasiripour S; Ansarinejad N; Zarei M
    J Clin Pharmacol; 2020 Oct; 60(10):1362-1366. PubMed ID: 32519800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequent off-label use of fondaparinux in patients with suspected acute heparin-induced thrombocytopenia (HIT)--findings from the GerHIT multi-centre registry study.
    Schindewolf M; Steindl J; Beyer-Westendorf J; Schellong S; Dohmen PM; Brachmann J; Madlener K; Pötzsch B; Klamroth R; Hankowitz J; Banik N; Eberle S; Kropff S; Müller MM; Lindhoff-Last E
    Thromb Res; 2014 Jul; 134(1):29-35. PubMed ID: 24703295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fondaparinux for the treatment of suspected heparin-induced thrombocytopenia: a propensity score-matched study.
    Kang M; Alahmadi M; Sawh S; Kovacs MJ; Lazo-Langner A
    Blood; 2015 Feb; 125(6):924-9. PubMed ID: 25515959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fondaparinux in a critically Ill patient with heparin-induced thrombocytopenia: A case report.
    He Y; He H; Liu D; Long Y; Su L; Cheng W
    Medicine (Baltimore); 2018 Sep; 97(37):e12236. PubMed ID: 30212955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rivaroxaban and apixaban for the treatment of suspected or confirmed heparin-induced thrombocytopenia.
    Cirbus K; Simone P; Austin Szwak J
    J Clin Pharm Ther; 2022 Jan; 47(1):112-118. PubMed ID: 34704283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fondaparinux as a treatment option for heparin-induced thrombocytopenia.
    Papadopoulos S; Flynn JD; Lewis DA
    Pharmacotherapy; 2007 Jun; 27(6):921-6. PubMed ID: 17542773
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cost-effectiveness of argatroban treatment in heparin-induced thrombocytopenia: the effect of early versus delayed treatment.
    Arnold RJ; Kim R; Tang B
    Cardiol Rev; 2006; 14(1):7-13. PubMed ID: 16371760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A case of unsuccessful treatment of heparin-induced thrombocytopenia (HIT) with fondaparinux.
    Miranda AC; Donovan JL; Tran MT; Gore JM
    J Thromb Thrombolysis; 2012 Jan; 33(1):133-5. PubMed ID: 21947717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging Role of Direct Oral Anticoagulants in the Management of Heparin-Induced Thrombocytopenia.
    Tran PN; Tran MH
    Clin Appl Thromb Hemost; 2018 Mar; 24(2):201-209. PubMed ID: 28301915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heparin-induced thrombocytopenia treated with fondaparinux: single center experience.
    Dulicek P; Ivanova E; Kostal M; Fiedlerova Z; Sadilek P; Hirmerova J
    Int Angiol; 2020 Feb; 39(1):76-81. PubMed ID: 31782283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Strategies for the management of suspected heparin-induced thrombocytopenia: a cost-effectiveness analysis.
    Patrick AR; Winkelmayer WC; Avorn J; Fischer MA
    Pharmacoeconomics; 2007; 25(11):949-61. PubMed ID: 17960953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Standardizing the management of heparin-induced thrombocytopenia.
    Fugate S; Chiappe J
    Am J Health Syst Pharm; 2008 Feb; 65(4):334-9. PubMed ID: 18238772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.